Table 3.
Extent of marker elevation at diagnosis.
| bHCG [x-fold of ULN] | AFP [x-fold of ULN] | LDH [x-fold of ULN] | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | Min | Median (Q1 - Q3) | Max | Min | Median (Q1 - Q3) | Max | Min | Median (Q1 - Q3) | Max | |
| All GCT patients | 422 (100.0%) | 0.03 | 0.46 (0.41 - 3.12) | 749063.67 | 0.05 | 0.40 (0.24 - 1.04) | 5906.58 | 0.01 | 0.89 (0.76 - 1.10) | 17.00 |
| pT-stage | ||||||||||
| pT1 | 222 (52.6%) | 0.03 | 0.45 (0.41 - 1.08) | 749063.67 | 0.05 | 0.38 (0.23 - 0.86) | 5906.58 | 0.01 | 0.83 (0.72 - 0.96) | 17.00 |
| >pT1 | 200 (47.4%) | 0.03 | 1.03 (0.45 - 4.93) | 130974.14 | 0.08 | 0.48 (0.25 - 1.20) | 1630.46 | 0.03 | 0.97 (0.82 - 1.24) | 9.32 |
| p-valuea | <.0001 | 0.1126 | <.0001 | |||||||
| Histology | ||||||||||
| Seminoma | 254 (60.2%) | 0.03 | 0.45 (0.41 - 1.16) | 86.23 | 0.05 | 0.30 (0.22 - 0.47) | 2.81 | 0.01 | 0.88 (0.75 - 1.06) | 8.40 |
| Nonseminoma | 168 (39.8%) | 0.03 | 1.35 (0.45 - 18.65) | 749063.67 | 0.10 | 2.02 (0.49 - 13.02) | 5906.58 | 0.55 | 0.90 (0.78 - 1.12) | 17.00 |
| p-valuea | <.0001 | <.0001 | 0.0963 | |||||||
| Clinical stage | ||||||||||
| CS1 | 281 (66.6%) | 0.03 | 0.45 (0.41 - 1.31) | 560.26 | 0.05 | 0.36 (0.23 - 0.64) | 1630.46 | 0.01 | 0.83 (0.72 - 0.98) | 5.41 |
| CS2a,b | 95 (22.5%) | 0.18 | 0.73 (0.45 - 12.94) | 19427.83 | 0.13 | 0.50 (0.25 - 2.34) | 195.55 | 0.03 | 0.98 (0.84 - 1.13) | 8.40 |
| CS2c | 17 (4.0%) | 0.22 | 1.20 (0.41 - 30.19) | 28667.79 | 0.17 | 0.67 (0.45 - 1.93) | 1596.20 | 0.59 | 1.34 (0.95 - 2.48) | 3.80 |
| CS3 | 29 (6.9%) | 0.34 | 6.78 (0.79 - 70.86) | 749063.67 | 0.12 | 1.35 (0.42 - 51.31) | 5906.58 | 0.82 | 1.28 (0.96 - 1.68) | 17.00 |
| p-valuea | <.0001 | <.0001 | <.0001 | |||||||
| CS1 vs. >CS1 | ||||||||||
| CS1 | 281 (66.6%) | 0.03 | 0.45 (0.41 - 1.31) | 560.26 | 0.05 | 0.36 (0.23 - 0.64) | 1630.46 | 0.01 | 0.83 (0.72 - 0.98) | 5.41 |
| >CS1 | 141 (33.4%) | 0.18 | 1.31 (0.45 - 14.38) | 749063.67 | 0.12 | 0.59 (0.27 - 3.29) | 5906.58 | 0.03 | 1.04 (0.88 - 1.42) | 17.00 |
| p-valuea | <.0001 | <.0001 | <.0001 | |||||||
| CS1 vs. >CS1 (Seminoma) | ||||||||||
| CS1 | 201 (79.1%) | 0.03 | 0.45 (0.41 - 0.94) | 47.73 | 0.05 | 0.30 (0.22 - 0.46) | 2.12 | 0.01 | 0.83 (0.73 - 0.98) | 5.41 |
| >CS1 | 53 (20.9%) | 0.18 | 0.69 (0.45 - 3.37) | 86.23 | 0.13 | 0.28 (0.23 - 0.50) | 2.81 | 0.03 | 1.03 (0.88 - 1.58) | 8.40 |
| p-valuea | 0.0001 | 0.3529 | <.0001 | |||||||
| CS1 vs. >CS1 (Nonseminoma) | ||||||||||
| CS1 | 80 (47.6%) | 0.03 | 0.72 (0.43 - 4.86) | 560.26 | 0.10 | 2.27 (0.48 - 12.02) | 1630.46 | 0.55 | 0.81 (0.72 - 0.98) | 2.71 |
| >CS1 | 88 (52.4%) | 0.21 | 3.59 (0.45 - 39.12) | 749063.67 | 0.12 | 1.51 (0.49 - 20.16) | 5906.58 | 0.57 | 1.04 (0.87 - 1.31) | 17.00 |
| p-valuea | 0.0041 | 0.9671 | <.0001 | |||||||
a Mann-Whitney U test for comparisons of subgroups; Min minimum value, Max maximum value, ULN upper limit of norm, Q1: first quartile, Q3: third quartile.